Stock AnalizMedtronic plc MDT
Biotechnology: Electromedical & Electrotherapeutic Apparatus · data as of November 13, 2026
Medtronic plc (MDT) is a healthcare company listed in the US with a market value of about $131.6B. In the twelve months to July 31, 2026 it had revenue of $37.5B and net income of $5.2B, a net margin of 13.9%.
Its overall Stock Analiz score is 2.2 out of 5 (weak). The strongest part is shareholder returns (5/5); the weakest is value (0/5).
Key numbers: a P/E of 25.3, a price to free cash flow of 21.5, 5-year revenue growth of 4% a year, a 5-year average ROIC of 6%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 16% below the current price.
Score: 2.2 / 5
Checks passed
- Profit margin improving
- Strong R&D investment or growth above 20%
- Profitable 5 years in a row
- Positive free cash flow
- Interest covered more than 5 times
- Liabilities below 60% of assets
- Pays a dividend
- Share count down over 3 years (buybacks)
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $37.5B | $36.4B | $33.5B | $32.4B | $31.2B | $31.7B | $30.1B | $28.9B | $30.6B | $30.0B | $29.7B |
| Net income | $5.2B | $4.8B | $4.7B | $3.7B | $3.8B | $5.0B | $3.6B | $4.8B | $4.6B | $3.1B | $4.0B |
| Free cash flow | $6.1B | $5.4B | $5.2B | $5.2B | $4.6B | $6.0B | $4.9B | $6.0B | $5.9B | $3.6B | $5.6B |
| EPS (diluted) | $4.07 | $3.73 | $3.61 | $2.76 | $2.82 | $3.73 | $2.66 | $3.54 | $3.41 | $2.27 | $2.89 |
| Net margin | 13.9% | 13.2% | 13.9% | 11.4% | 12.0% | 15.9% | 12.0% | 16.6% | 15.2% | 10.4% | 13.6% |
| ROIC | — | 6.5% | 6.4% | 5.1% | 5.0% | 6.8% | 5.3% | 4.9% | 7.3% | 4.7% | 5.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 26 analysts is $105.00, 2% above the current price; targets range from $85.00 to $121.00; the consensus rating is “Buy”; expected EPS is $5.98 for the fiscal year ending April 30, 2027.
Frequently asked questions
What is Medtronic’s P/E ratio?
About 25.3, based on the last twelve months of diluted earnings per share (forward P/E about 17.3).
Is Medtronic stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 16% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Medtronic pay a dividend?
Yes. The dividend yield is about 2.83%, and it has paid dividends for 10 years in our data.
Is Medtronic a good stock to buy?
We do not give buy or sell advice. Medtronic scores 2.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.